Related by context. All words. (Click for frequent words.) 74 GORE VIABAHN Endoprosthesis 64 Biolimus A9 62 NAVISTAR R 62 Eluting Coronary Stent System 62 Cypher Sirolimus 62 renal artery stenting 61 superficial femoral 61 PFO migraine 61 Embolic Protection System 61 Peripheral Arterial 61 Randomized Evaluation 61 Percutaneous Transluminal Coronary Angioplasty 61 sirolimus eluting 61 Sirolimus eluting 61 Patency 61 NEVO 60 PRECISE 60 Intravitreal 60 Prospective Randomized 60 epoetin alpha 60 everolimus eluting stents 60 Intravascular 59 Prospective Randomized Trial 59 carotid artery stenting CAS 59 paclitaxel eluting 59 Stent Restenosis 59 Nebulized 59 randomized multicenter trial 59 Fully Covered Stent 59 candesartan cilexetil 59 vapreotide acetate 59 zotarolimus 59 liposome injection 59 transesophageal 59 sulodexide 59 eluting stent 59 Ranolazine 59 Sirolimus eluting Coronary Stent 59 J Am Coll 58 cinacalcet 58 PROMUS Element Stent 58 GAMMAGARD 58 thickness IMT 58 XIENCE V PROMUS Stent 58 Carotid 58 Aneurysm Repair 58 Pegylated Liposomal Doxorubicin 58 TM Drug Eluting 58 Pivotal Trial 58 WallFlex Biliary RX 58 V Everolimus Eluting Coronary 58 treating abdominal aortic 58 Pivotal Phase III 58 Aggressive Drug Evaluation 58 Parathyroid Hormone 58 ISAR TEST 58 Fractional Flow Reserve 58 MIVI III 58 Controlled Trial 58 descending thoracic 58 MAGE A3 ASCI 58 #:#-# [031] 58 restenotic lesions 58 bazedoxifene selective estrogen receptor 58 Ziprasidone 57 Unfractionated Heparin 57 Optical Coherence Tomography 57 HeartNet 57 Thoracic Endoprosthesis 57 NEVO TM 57 HepaSphere 57 hemodynamically significant 57 Vascular Wrap 57 ACTOS ® 57 NATRECOR ® 57 carotid endarterectomy CEA 57 Carotid Revascularization Endarterectomy vs. 57 transthoracic 57 Bare Metal Stent 57 Resolute stent 57 Myocardial Infarction TIMI 57 MiStent DES 57 Prostate AdenoCarcinoma Treatment 57 Mycophenolate Mofetil 57 phase IIIb 57 mm Stent 57 CYPHER R Sirolimus eluting 57 acute peripheral arterial 57 TM Everolimus Eluting 57 STARFlex R 57 ZOLINZA 56 interferon gamma 1b 56 SANVAR 56 HuMax EGFr 56 pan HDAC inhibitor 56 Eluting Stent 56 Spiriva Handihaler 56 endoluminal stent graft 56 Percutaneous Tibial Nerve Stimulation 56 Coronary Stent 56 STRIDE PD 56 Crystalens AO 56 dual endothelin receptor antagonist 56 TAXUS Liberte Stent 56 MR Angiography 56 Hormone Refractory Prostate Cancer 56 RAVEL 56 aspirin clopidogrel 56 Study Evaluating 56 Cardiol 56 lexidronam injection 56 dimeglumine 56 Xelox 56 Cypher Stent 56 Meets Primary Endpoint 56 QuadraSphere 56 Initiate Clinical Trial 56 Emboshield 56 transabdominal 56 nonrandomized 56 STARFlex 56 posterolateral fusion 56 transcranial Doppler ultrasound 56 CINQUIL 56 TAXUS Liberté 56 Placebo Controlled Trial 56 metaplasia 56 carotid IMT 56 corneal curvature 56 samarium Sm 56 Ablation System 56 Drug Eluting 56 Myocardial Perfusion Imaging 56 prucalopride 56 vs. Angiography 56 TLK# 56 Accelerated Partial Breast Irradiation 55 TREDAPTIVE 55 CYPHER ® Sirolimus eluting 55 ABSORB 55 arsenic trioxide injection 55 catheter occlusion 55 Intracoronary 55 Pivotal Study 55 cobalt chromium alloy 55 Vidaza azacitidine 55 pain palliation 55 Phase III Clinical Trial 55 clevidipine 55 Dose Ranging Study 55 TAXUS VI 55 mechanical thrombectomy 55 Coronary Artery Bypass Graft 55 zotarolimus eluting stent 55 TUMT 55 antiarrhythmic drug 55 Pafuramidine 55 multicenter randomized placebo controlled 55 noninferiority 55 Angiographic 55 Clinical Outcome 55 assessing T DM1 55 metastatic malignant 55 efficacy tolerability 55 THE ORLANDO FLA. 55 carotid artery stenting 55 ExTRACT TIMI 55 ASTEROID 55 Completes Patient Enrollment 55 prospective multicenter study 55 Acute Myocardial Infarction 55 postmenopausal osteoporotic women 55 unfractionated heparin UFH 55 aortoiliac 55 Novel Oral 55 gauge vitrectomy 55 TAXUS Liberte Long 55 PROTEGE 55 femoral stem 55 FDA APPROVES 55 cediranib 55 Bosentan 55 cardiac repolarization 55 JAK Inhibitor 55 Trandolapril 55 induced macular edema 55 PHASE III 55 Intracranial Aneurysms 55 inhaled iloprost 55 oral anticoagulation 55 Infarct 55 PERSEUS 55 clinically meaningful efficacy 55 MERLIN TIMI 55 corneal inlay 55 multicenter randomized controlled 55 Matrix Phase 2b 55 Histologic 55 multicentre randomized 55 Randomized Clinical Trial 55 RE LY 54 Risk Stratification 54 See CLINICAL PHARMACOLOGY 54 computed tomographic 54 SPIRIT FIRST 54 liposomal doxorubicin 54 TAXUS Element Paclitaxel Eluting 54 MGuard ™ 54 Oral Fingolimod 54 Aliskiren 54 everolimus eluting 54 GORE TAG ® 54 RE LY ® 54 IIIa inhibitor 54 EURIDIS 54 STARFlex ® 54 vidofludimus 54 Refractory Angina 54 Acute Myocardial 54 riociguat 54 digital subtraction angiography 54 antithrombotic agents 54 aneurysms AAA 54 Cardiotoxicity 54 Left Ventricular 54 Paclitaxel Eluting 54 Biphasic 54 Complicated Skin 54 hemostatic efficacy 54 immunohistochemical 54 Central Venous Catheter 54 SYNERGY Stent 54 Phase Ib study 54 Intervention Effectiveness 54 Pharmacodynamics 54 sacral nerve stimulation 54 5 FU leucovorin 54 percutaneous catheter 54 SR# [004] 54 Endeavor Drug Eluting 54 RENAL 54 Phase IIb Clinical Trial 54 CARE HF 54 Microwave Ablation System 54 dual antiplatelet 54 Betaferon R 54 Laser Lok 54 Thrombolysis 54 Stenting 54 Meta Analysis 54 Vascugel ® 54 Int J Radiat Oncol 54 sirolimus eluting stents 54 prospective multicenter randomized 54 EnteroMedics proprietary neuroblocking technology 54 Pemetrexed 54 distal femoral 54 Monitoring ABPM 54 biliary tract cancer 54 thalidomide Thalomid 54 thickness CIMT 54 MGuard TM 54 VerifyNow 54 bi ventricular pacing 54 StarClose 54 II Clinical Trial 54 Antiplatelet 54 PROMUS R 54 Doppler echocardiography 54 IIIb 54 HDL Selective Delipidation 54 bevacizumab Avastin R 54 TO AVOID PREGNANCY WHILE 54 recombinant tissue plasminogen 53 Myocardial Infarction Study 53 Achieves Primary Endpoint 53 MGd 53 Acute Ischemic Stroke 53 Clinical Trial Results 53 Interagency Registry 53 interobserver 53 Breast Cancer Assay 53 embolic protection device 53 preclinical efficacy 53 acetabular components 53 coronary sinus 53 Randomized Double blind 53 OmniWave 53 Randomised 53 proximal tibial 53 lumbar interbody fusion 53 ostial 53 Rubicon Filter 53 BRIM2 53 R Saizen R 53 Phase 2b Clinical Trial 53 Pivotal Clinical Trial 53 somatostatin analog 53 rt PA 53 Multicenter 53 intravitreal bevacizumab 53 CardioFit 53 EchoCRT 53 MIST II 53 hydroxymethyl coenzyme 53 J Am Soc 53 functional mitral regurgitation 53 oral antiplatelet therapy 53 percutaneous injection 53 transcranial Doppler 53 Diamondback #deg 53 drug eluting stent DES 53 Relapsing Multiple Sclerosis 53 Diastolic Heart Failure 53 occipital nerve stimulation 53 IN PATIENTS WITH 53 stereotactic radiotherapy 53 cardiopulmonary bypass CPB 53 anti arrhythmic 53 Tocilizumab 53 coronary stent merged 53 By JENNIFER LEARN 53 cTnI 53 CIMZIA TM certolizumab pegol 53 novel oral anticoagulant 53 Multivessel Evaluation 53 carotid stent 53 #:#-# [023] 53 Catheter Ablation 53 Phase 2b Study 53 cardiac perfusion 53 prospective randomized controlled 53 intramedullary nailing 53 Squalamine 53 TAXUS V 53 intima media thickness IMT 53 APPRAISE 53 LEVAQUIN ® 53 Tezampanel 53 CellSearch ™ 53 generation purine nucleoside 53 RE LY trial 53 J Clin 53 Phase IIb Trial 53 Pivotal Phase 53 Randomized Controlled Trials 53 ultrastructural 53 PREVAIL 53 PressureWire 53 BrachySil TM 53 Controlled Study 53 fosbretabulin 53 saphenous vein graft 53 rotational angiography 53 Pooled Analysis 53 clot retrieval 53 Lucentis ranibizumab Genentech 53 plasma kallikrein inhibitor 53 Phase 2a Clinical Trial 53 pulmonary artery banding 53 transient elastography 53 occlusion CRVO 53 suprarenal 53 Intervention Effectiveness CATIE 52 NSABP B 52 Intravail R 52 intravascular ultrasonography 52 Drug Eluting Stents 52 RISKS UNCERTAINTIES AND ASSUMPTIONS 52 Double Blind Randomized 52 proximal humerus 52 stent binary restenosis 52 IMPACT IMmunotherapy 52 First Patient Enrolled 52 uncemented 52 ALA PDT 52 Carotid Stenting 52 Circulatory Support 52 GOUT 52 Deferiprone 52 interstitial brachytherapy 52 malignant ascites 52 Zenvia Phase III 52 Prospective Multicenter 52 Atherosclerotic 52 Genomic Grade 52 Chronic Heart Failure 52 virus HCV protease inhibitor 52 recurrent glioblastoma multiforme 52 carotid revascularization 52 Randomized controlled 52 ENDEAVOR II 52 Vernakalant 52 Safinamide 52 Antiviral Activity 52 acetabular component 52 FEMALES SHOULD BE ADVISED 52 NP2 Enkephalin 52 Combination REOLYSIN R 52 XIENCE TM 52 Tibial 52 TAXUS ATLAS 52 ClearPath HDR 52 IMPACT DCM 52 aminolevulinic acid 52 prospective nonrandomized 52 Phase 1a clinical 52 * LW# * 52 SIDE EFFECTS CHEAP ONLINE 52 Abstract Free Full Text 52 interobserver reliability 52 intramedullary 52 mitral annular 52 Tomographic 52 OMS# 52 abstr 52 TRANSFORMS 52 recurrent metastatic 52 THAT ARE DIFFICULT TO 52 PICSO ® 52 thromboembolic complications 52 extracranial 52 Phase III ADT 52 #-# Full Text 52 Stenting Trial CREST 52 Initiates Clinical 52 monophasic 52 distal femur 52 p# inhibitor 52 CLORETAZINE TM VNP#M 52 ImmuKnow R 52 SABCS 52 Completes Enrollment 52 ABLYNX 52 CoreValve System 52 icatibant 52 ACE Inhibitor 52 Phase Ib Clinical Trial 52 photocoagulation 52 Randomized Double Blind Placebo 52 endothelin antagonist 52 evaluating tivozanib 52 STENT 52 Arimidex Tamoxifen Alone 52 Hemodynamic 52 Histological 52 briakinumab 52 orally inhaled migraine 52 orally administered inhibitor 52 Randomized Double Blind 52 randomized controlled clinical 52 cetuximab Erbitux R 52 Hsp# Inhibitor 52 phase IIb study 52 #:#-# [025] 52 peripheral arterial 52 radiolucent 52 Peginterferon Alfa 2a 52 CRMD# 52 boosted protease inhibitor 52 thetreatment 52 talar 52 total hip arthroplasties 52 RAPAFLO R 52 Zarnestra 52 myocardial necrosis 52 SYNTAX trial 52 Temsirolimus 52 NMIBC 52 reflux esophagitis 52 HALTS 52 Dacogen decitabine 52 multicenter multinational 52 Events MACE 52 RECORD1 52 Dabigatran etexilate 52 randomized multicenter 52 symptomatic intracranial 52 Alair System 52 Clinical Antipsychotic Trials 52 Ancrod 52 pretransplant 52 reslizumab 52 AngioJet thrombectomy 52 pulmonary arterial 51 Trial Evaluating 51 trabecular 51 Pertuzumab 51 calcaneal 51 #:#-# [028] 51 Pharmacokinetics PK 51 AFRS TM 51 phase III isavuconazole 51 CUSTOM III 51 multicenter randomized 51 prospective multicenter 51 ADAGIO study 51 HCl capsules 51 Zilver PTX stent 51 Stereotactic Radiosurgery 51 Eur J Endocrinol 51 ENDEAVOR III 51 antiangiogenic agent 51 INABILITY TO SATISFY DEBT 51 cisplatin gemcitabine 51 multicenter randomized Phase III 51 intradiscal 51 femoral fractures 51 mg/m2 cohort 51 intracoronary 51 alteplase 51 multicenter prospective 51 proximal femoral 51 CYP#A# CYP#D# 51 intervertebral 51 COR Analyzer 51 Sirolimus Eluting Stent 51 nomograms 51 DVT prophylaxis 51 doi #.#/fj.#-# 51 Left Ventricular Dysfunction 51 cisplatin vinorelbine 51 ADVANCE PD 51 Edge STudy 51 Echocardiographic 51 TAXUS IV 51 ZoMaxx 51 ZD# [001] 51 noninvasive outpatient 51 Virtual Histology 51 FDG PET imaging 51 Rigel R# 51 Cellulaze 51 INTRABEAM 51 BrachySil ™ 51 Crystalens HD 51 non valvular atrial 51 carotid intima media 51 Zemplar Capsules 51 prospective randomized multicenter 51 Corus CAD 51 PREDICTIVE 51 VisuMax 51 Curr Opin 51 XIENCE 51 immunotherapeutic vaccine 51 landmark ATHENA trial 51 eprotirome 51 Tasigna prolongs 51 IN COMBINATION WITH 51 Am J Cardiol 51 GW# [003] 51 Eur J 51 POLYSHIELD ® POLYCLEAR ® 51 Viatronix V3D Colon 51 Smartlipo MPX 51 SYNTAX Score 51 concurrent chemoradiation 51 PresbyLens ® 51 R bendamustine hydrochloride 51 intranasal delivery 51 ® pioglitazone HCl 51 ACUITY trial 51 medicated stent 51 efficacy evaluable 51 CALGB # [002] 51 NTx ® -# 51 AmpliChip 51 J Am Acad 51 mGluR5 negative 51 HER2 antibody 51 Therapy VMAT 51 atherosclerotic renal artery stenosis 51 oncologic outcomes 51 neuroprotectant 51 liver resection 51 obturator 51 transcranial 51 Pressemitteilung ist der jeweilige 51 glenoid component 51 CYT# potent vascular disrupting 51 electrophysiologic 51 aleglitazar 51 placebo controlled clinical 51 ORENCIA ® 51 Histopathologic 51 endoluminal 51 Diabetic Macular Edema 51 Coronary CTA 51 HER2 expression 51 femoral head 51 DNA methylation markers 51 prospective multicentre 51 ablative therapy 51 buccal spray 51 SPIRIT IV 51 hoFH 51 Adjunctive Therapy 51 RhuDex 51 rFVIIa 51 femoral component 51 levodopa induced dyskinesia 51 EOquin TM 51 Onconase 51 somatosensory evoked potentials 51 Carotid WALLSTENT 51 CHAMPION PCI 51 Drug Eluting Stent System 51 randomized controlled Phase 51 ENDEAVOR IV 51 Skin sterol 51 novel VDA molecule 51 NuroPro PD 51 phase IIb III 51 ACTIVE W 51 osteoid 51 oral transmucosal fentanyl citrate 51 ATACAND 51 Randomized Phase 51 MEND CABG 51 defibrillator CRT D 51 Transcranial 51 fibrillation AF 51 Antigen Specific 51 multidose 51 cannulated 51 mcg QD 51 PD LID 50 chemoradiation therapy 50 pharmacokinetic PK study 50 phakic 50 femoral neck bone 50 Octreolin 50 multicenter placebo controlled 50 ximelagatran 50 death reinfarction 50 milrinone 50 aliskiren amlodipine 50 AZILECT ® 50 MelaFind R 50 placebo controlled Phase III 50 refractory chronic lymphocytic 50 RNFL 50 EVEREST II 50 Free Full Text 50 Phase 2a Study 50 non resectable metastatic 50 denileukin diftitox 50 Anti Bacterial Envelope 50 QRS interval 50 COPERNICUS 50 iliac 50 Hexvix 50 sunitinib Sutent 50 Nephrol 50 GRAVITAS trial 50 neratinib 50 Retisert 50 VNP#M 50 metaglidasen 50 bifurcation stent 50 ClosureFAST 50 Anavex #-# 50 resynchronization therapy 50 Feasibility Trial 50 Aflibercept 50 DCCR 50 magnetic resonance CMR 50 Randomized Study 50 Microvolt T Wave Alternans 50 Non Alcoholic Steatohepatitis 50 COVER YOUR BODY 50 OvaDx 50 FIRMAGON R 50 Antigen CEA 50 phase IIa clinical 50 subconjunctival injection 50 Nesiritide 50 thorough QT 50 mg kg BID 50 intracardiac 50 Injectable Bone Graft 50 MADIT II 50 coronary intervention 50 Magnetic resonance 50 Custom NX 50 Phase Ib II 50 Bare Metal Stents 50 Cand5 50 PEGINTRON TM 50 Radiographic 50 #:#-# [020] 50 ELACYT 50 Stent Implantation 50 myocardial revascularization 50 anti arrhythmic drug 50 Arimidex anastrozole 50 PACCE 50 ODT metoclopramide HCl PEPCID 50 electrocardiography ECG 50 SEPET TM 50 PROLARIS 50 proximal femur 50 ACOMPLIA R 50 Trofex 50 EP #R 50 Initiated Phase 50 CA9 SCAN 50 Deforolimus 50 CHEAP ONLINE PHARMACY BEST 50 PROWESS 50 PRICE GREAT DISCOUNT FREE 50 Electronic Brachytherapy 50 Embosphere Microspheres 50 histologic findings 50 powder diffraction 50 Abstract Full Text 50 BOLDER II 50 urolithiasis 50 multicenter clinical trials 50 recurrent GBM 50 CYPHER Stent 50 Meta analyzes 50 aneurysm sac 50 NIR spectroscopy 50 RHEO 50 medial longitudinal 50 echocardiographic parameters 50 radiotherapeutic 50 phase Ib 50 undergoing elective percutaneous 50 AWAY FROM WINDOWS 50 ASSERT 50 Pharmacokinetic Study 50 Randomized Controlled Trial 50 Arch Neurol 50 REALITY Trial 50 subtrochanteric 50 investigational antiplatelet 50 prasugrel Effient 50 holmium laser 50 NSABP C 50 nadolol 50 Phase #/#a 50 Pyridorin 50 substudy 50 V3D Colon 50 Toraymyxin 50 HORIZONS AMI trial 50 Phase III multicenter 50 것이다 50 DEEP AF 50 CHEAP ONLINE PHARMACY LOW 50 elastic modulus 50 percutaneous interventions 50 ThermoDox R 50 chronic thromboembolic pulmonary 50 multiplanar 50 Proellex TM 50 CLARITY study 50 Kit v2 50 left ventricular LV 50 REG1 50 Ann Surg 50 Phase IIIb clinical 50 laser Doppler 50 CaPSURE 50 multimodality imaging 50 CD3 monoclonal antibody 50 peritumoral 49 photoprotective drug 49 azilsartan medoxomil 49 Metabolic Efficiency 49 imexon 49 Edwards SAPIEN valve 49 SELDI TOF MS 49 Endovascular Valve Edge 49 Trobalt 49 Resolute DES 49 brivaracetam 49 Orally Active 49 ALN HPN 49 Abstract Number 49 doxorubicin docetaxel 49 LENALIDOMIDE 49 occlusion PAO 49 Long Lesion 49 coronary drug eluting 49 SIR Spheres 49 Clin Oncol 49 vein ablation 49 Exploratory IND 49 Subarachnoid hemorrhage 49 Randomized Phase II 49 TH# [003] 49 3 registrational trial 49 PRECISE trial 49 CELLO 49 Myoblast 49 Randomized clinical trials 49 ancrod 49 bone ingrowth 49 CARDIOVASCULAR 49 cardiac resynchronisation therapy 49 EECP ® therapy 49 F FDG PET 49 cardiac magnetic resonance 49 thoracolumbar 49 antihypertensive therapies 49 Solorel 49 의 을 49 doxorubicin cyclophosphamide 49 J Clin Oncol 49 WavSTAT 49 RGOODMAN@ENQUIRER.COM 49 interferon beta therapy 49 IntroductionThe 49 MOVIPREP ® 49 dosimetric 49 total knee arthroplasties 49 hypertrichosis occurred 49 distal tip 49 BRAF inhibitor 49 cardioverter defibrillator 49 THESE CONDITIONS NOT 49 이다 49 Panzem NCD 49 PEG IFN 49 Cardiac Resynchronization Therapy 49 ECLS 49 echocardiographic 49 Biol Phys 49 VESTASYNC 49 dissolving clots 49 SORIN 49 OvaRex MAb 49 DRILL HOLE 49 medically refractory 49 ongoing Phase 1b 49 Radient Pharmaceutical current 49 MicroThermX 49 angiotensin receptor 49 RE COVER 49 optical coherence tomography 49 J Allergy Clin 49 Endarterectomy 49 brivanib 49 Safety Tolerability 49 SNT MC# 49 Sideguard ® 49 efficacy endpoint 49 Placebo Controlled 49 RISKS UNCERTAINTIES AND OTHER 49 angiographically 49 Phase III confirmatory 49 lens IOL 49 XYOTAX TM 49 nanopharmaceutical 49 PROTECT II 49 #:#-# [029] 49 Double Blind Placebo 49 mechanical dyssynchrony 49 retrospective observational study 49 implantable centrifugal rotary 49 Tanespimycin 49 Sensitivity analyzes 49 vessel occlusion 49 endocardial 49 Gynecol 49 Antisoma AS# 49 etanercept Enbrel 49 fidaxomicin Phase 3 49 septal 49 Stenting Trial 49 BioSTAR ® 49 proximal tibia 49 Severe Sepsis 49 IS ASSOCIATED WITH 49 PHOSPHATE 49 acetabular 49 Abbott bioabsorbable stent 49 dasatinib Sprycel ® 49 extensor mechanism 49 Phase #b/#a 49 capsulotomy 49 ACTIQ ® 49 Pirfenidone 49 Solid Tumors criteria 49 로 49 OnDose 49 Arch Intern Med 49 ZYBRESTAT TM 49 BRIM3 48 Delayed Graft Function 48 Syndr 48 ultrasonographic 48 oral salmon calcitonin 48 EnRhythm MRI SureScan pacing 48 distally 48 multicentre 48 multivariate Cox 48 FASEB J. 48 Crit Rev 48 Kaplan Meier curves 48 ABSORB trial 48 Huntexil 48 PFO closure 48 phase IIb clinical 48 MDCT angiography 48 Mol Cell 48 Surgical resection 48 Schematic representation 48 acetabular dysplasia 48 intralesional 48 BY JANE PRENDERGAST 48 Initiate Phase II 48 Cardiac Allograft Rejection 48 number NCT# ClinicalTrials.gov 48 Intergroup Exemestane Study 48 Optical coherence tomography 48 TO PATIENTS 48 multicenter Phase III 48 BY MOODY 'S 48 Phase III ThermoDox 48 AIM HIGH 48 XIENCE V Stent System 48 SF #v# 48 laser photocoagulation 48 radiation dosimetry 48 satraplatin Phase 48 EINSTEIN DVT 48 FDG-PET/CT 48 CardioPass 48 CLINICAL TRIAL 48 ENDEAVOR clinical 48 ESTIMATES THAT WHILE CONSIDERED 48 superior mesenteric artery 48 Multicenter Randomized 48 hip arthroplasty 48 Doxil ® 48 covariance ANCOVA 48 Akt inhibitor 48 perfusion imaging 48 INFORMATION INVOLVE KNOWN AND 48 Am J Respir 48 Alvesco R 48 SUTENT ® 48 confirmatory clinical 48 Macroscopic 48 OHR/AVR# 48 도 48 platelet aggregation inhibitor 48 scleral 48 chemotherapeutic regimen 48 Phase III Trial 48 ritonavir boosted danoprevir 48 Multicenter Randomized Double 48 Diabetic Macular Edema DME 48 transvaginal sonography 48 BOLDER 48 ACCOMPLISH 48 PI3 kinase inhibitors 48 oxybutynin topical gel 48 symptomatic paroxysmal AF 48 plain radiographs 48 Proc Am Soc 48 mg BID dose 48 anthropometric measures 48 Premarket Approval 48 multicenter Phase II 48 Stent Thrombosis 48 vastus lateralis 48 trochanteric 48 ALLEVIATE 48 VBLOC 48 myoblast therapy 48 prospective observational 48 Lucentis ranibizumab 48 Crit Care Med 48 Acute Decompensated Heart Failure 48 transrectal ultrasound 48 ostium 48 ELIQUIS 48 Glybera 48 MEND CABG II 48 CustomVue 48 TROPIC 48 BR.# 48 metaphyseal 48 CEUS 48 metastatic castration resistant 48 Randomized Comparison 48 MMP inhibitor 48 Tipranavir 48 quantitative computed tomography 48 Solution XOPENEX HFA 48 Orthop Surg 48 randomized blinded 48 PrandiMet